Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRONULIFE NosRelieve
- Development stage
- Unknown
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
PRONULIFE NosRelieve (also marketed as BabyAllieve for pediatric applications) is a functional probiotic formulation developed by GLAC Biotech Co., Ltd. (豐華生物科技). It features a proprietary multi-strain blend of 3-4 high-quality *Lactobacillus* strains, including *Lactobacillus reuteri* GL-104. The product is designed to modulate immune responses and alleviate allergic symptoms, particularly targeting respiratory and skin-related sensitivities. It utilizes GLAC's proprietary PRONEX micro-encapsulation technology to ensure the stability and viability of the probiotic strains throughout their shelf life. Administered orally as a dietary supplement or functional food ingredient, PRONULIFE NosRelieve is supported by clinical studies and global patents validating its safety and efficacy in immune and allergy modulation for both adults and children.
- Brand names
- PRONULIFE NosRelieveBabyAllieve
Beyond the preview
Go deeper on PRONULIFE NosRelieve.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRONULIFE NosRelieve.